Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation

Abstract

Background and study aims Endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic biliary sphincterotomy (EBS) or endoscopic papillary balloon dilation (EPBD) are common techniques of biliary decompression. Potential risks include gastrointestinal hemorrhage, which can be increased by antiplatelet agents, anticoagulants (AC) and/or novel oral anticoagulants (NOACs) (ie. apixaban, dabigatran and rivaroxaban).

The study aim is to evaluate the safety/efficacy of an alternative technique, minimal-EBS plus EPBD (m-EBS + EPBD), in individuals for whom clopidogrel, AC, and/or NOACs cannot be interrupted due to high cardiovascular or thromboembolic risk.

Patients and methods Patients undergoing m-EBS + EPBD while taking clopidogrel and/or AC were retrospectively evaluated at two United States tertiary care centers for efficacy, GIB and procedure-related, cardiovascular and thromboembolic adverse events (AE).

Results Ninety-five patients were identified [55 = clopidogrel and 45 = AC (31.1 % NOACs)]. The main indication for ERCP was choledocholithiasis (34 %). 100 % clinical improvement and 97.9 % endoscopic success were found. The incidence of AE was 5.3 %. There was a 4.2 % incidence of gastrointestinal hemorrhage (2 cases requiring endoscopic intervention). Both severe gastrointestinal hemorrhages also experienced the cases of post-ERCP pancreatitis, and 2 /3 of cholangitis (all aspirin + AC). There was 1cardiovascular event (non-ST elevation myocardial infarction), and no thromboembolic events.

Conclusions Minimal-EBS + EPBD is an effective and safe therapy with an incidence of gastrointestinal hemorrhage of 4.2 %, (2.1 % requiring endoscopic intervention), for patients on clopidogrel and/or AC, with a high risk for cardiovascular/thromboembolic events.

• References

• 1 Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. J Clin Gastroenterol 2001; 32: 106-118
• 2 Adler DG, Baron TH, Davilla RE. et al. ASGE guidelines: the role of ERCP in diseases of the biliary tract. Gastrointest Endosc 2005; 62: 1-8
• 3 Venu RP, Geenen JE. Overview of endoscopic sphincterotomy for common bile duct stone. Gastrointest Endosc Clin N Am 1991; 1: 3-26
• 4 Foutch G. Endoscopic management of large common bile duct stones. Am J Gastroenterol 1991; 86: 1561-1565
• 5 Seitz JH, Bapaye A, Bohnacker S. et al. Advances in therapeutic endoscopic treatment of common bile duct stones. World J Surg 1998; 22: 1133-1144
• 6 Minami A, Nakatsu T, Uchida N. et al. Papillary dilation vs sphincterotomy in endoscopic removal of bile duct stones: a randomized trial with manometric function. Dig Dis Sci 1995; 40: 2550-2554
• 7 Bergman JJ, Rauws J EA, Fockens P. et al. Randomized trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. Lancet 1997; 349: 1124-1129
• 8 Ochi Y, Mukawa K, Kiyosawa K. et al. Comparing the treatment outcomes of endoscopic papillary dilation and endoscopic sphincterotomy for removal of bile duct stones. J Gastroenterol Hepatol 1999; 14: 90-96
• 9 Stefanidis G, Karamanolis G, Viazis N. et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis. Gastrointest Endosc 2003; 57: 192-197
• 10 Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc 2007; 66: 283-290
• 11 Freeman ML, Nelson DB, Sherman S. et al. Complications of endoscopic biliary sphincterotomy. NEJM 1996; 335: 909-918
• 12 Masci E, Toti G, Mariani A. et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96: 417-423
• 13 Loperfido S, Angelini G, Benedetti G. et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10
• 14 Zhao HC, He L, Zhou DC. et al. Meta-analysis comparison of endoscopic papillary balloon dilatation and endoscopic sphincteropapillotomy. World J Gastroenterol 2013; 19: 3883-3891
• 15 Baron TH, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol 2004; 99: 1455-1460
• 16 Kim HG, Cheon YK, Cho YD. et al. Small sphincterotomy combined with endoscopic papillary large balloon dilation versus sphincterotomy. World J Gastroenterol 2009; 15: 4298-4304
• 17 Guo SB, Meng H, Duan ZJ. et al. Small sphincterotomy combined with endoscopic papillary large balloon dilation vs sphincterotomy alone for removal of common bile duct stones. World J Gastroenterol 2014; 20: 17962-17969
• 18 Bo QJ, Hua XL, Min CT. et al. Small Endoscopic Sphincterotomy plus Large-Balloon Dilation for Removal of Large Common Bile Duct Stones during ERCP. Pak J Med Sci 2013; 29: 907-912
• 19 Teoh AY, Cheung FK, Hu B. et al. Randomized trial of endoscopic sphincterotomy with balloon dilation versus endoscopic sphincterotomy alone for removal of bile duct stones. Gastroenterol 2013; 144: 341-345
• 20 Williams DO, Abbott JD, Kip KE. DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006; 114: 2154-2162
• 21 Iakovou I, Schmidt T, Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130
• 22 Mauri L, Hsieh WH, Massaro JM. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029
• 23 Hussain N, Alsulaiman R, Burtin P. et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25: 579-584
• 24 Samie AA, Stumpf M, Sun R. et al. Biliary-Pancreatic Endoscopic and Surgical Procedures in Patients under Dual Antiplatelet Therapy: A Single-Center Study. Clin Endosc 2013; 46: 395-398
• 25 Abdel Samie AA, Sun R, Vohringer U. et al. Safety of endoscopic sphincterotomy in patients under dual antiplatelet therapy. Hepatogastroenterology 2013; 60: 659-666
• 26 Onal IK, Parlak E, Akdogan M. et al. Do aspirin and non-steroidal anti-inflammatory drugs increase the risk of post-sphincterotomy hemorrhage – a case-control study. Clin Res Hepatol Gastroenterol 2013; 37: 171-176
• 27 Kawabe T, Komatsu Y, Tada M. et al. Endoscopic papillary balloon dilation in cirrhotic patients: removal of common bile duct stones without sphincterotomy. Endoscopy 1996; 28: 694-698
• 28 Komatsu Y, Kawabe T, Toda N. et al. Endoscopic papillary balloon dilation for the management of common bile duct stones: experience of 226 cases. Endoscopy 1998; 30: 12-17
• 29 Park DH, Kim MH, Lee SK. et al. Endoscopic sphincterotomy vs. endoscopic papillary balloon dilation for choledocholithiasis in patients with liver cirrhosis and coagulopathy. Gastrointest Endosc 2004; 60: 180-185
• 30 Adler DG, Haseeb A, Francis G. et al. Efficacy and safety of therapeutic ERCP in patients with cirrhosis: a large multicenter study. Gastrointestinal Endosc 2015; 83: 353-359
• 31 Hui CK, Lai KC, Yuen MF. et al. Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. Aliment Pharmacol Ther 2002; 16: 929-936
• 32 Hamada T, Yasunaga H, Nakai Y. et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy 2015; 47: 997-1004
• 33 Hassan C, Zullo A. Antiplatelet therapy and endoscopic procedures: eyes wide shut?. Endosc Int Open 2015; 3: E179-180
• 34 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326S-350S
• 35 Acosta RD, Abraham NS, Chandrasekhara V. et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83: 3-16
• 36 Boustiere C, Veitch A, Vanbiervliet G. et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011; 43: 445-461
• 37 Baron TH, Kamath PS, McBane RD. et al. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368: 2113-2124
• 38 Liao WC, Lee CT, Chang CY. et al. Randomized trial of 1-minute versus 5-minute endoscopic balloon dilation for extraction of bile duct stones. Gastrointest Endosc 2010; 72: 1154-1162
• 39 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 40 Vlavianos P, Chopra K, Mandalia S. et al. Endoscopic balloon dilatation versus endoscopic sphincterotomy for the removal of bile duct stones: a prospective randomized trial. Gut 2003; 52: 1165-1169
• 41 Fujita N, Maguchi H, Komatsu Y. et al. Endoscopic sphincterotomy and endo- scopic papillary balloon dilation for bile duct stones: a prospective randomized controlled multicenter trial. Gastrointest Endosc 2003; 57: 151-155
• 42 Arnold JC, Benz C, Martin WR. et al. Endoscopic papillary balloon dilation vs. sphincterotomy for removal of common bile duct stones: a prospective randomized pilot study. Endoscopy 2001; 33: 563-567